If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
2,015.00    11.00 (0.55%)
Bid:
2,013.00
Ask:
2,014.00
Spread: 1.00 (0.05%)
Market Cap: £80.71b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 May 2023 15:30

RNS Number : 4636Z
GSK PLC
15 May 2023
 

GSK plc (the 'Company')

Vesting of 2020 Performance Share Plan Top-Up Award

This notification sets out the vesting details of a "top-up" conditional share award made to the Chief Executive Officer (CEO) on 6 May 2020 under the GSK 2017 Performance Share Plan ('PSP'), following the approval of the 2020 Remuneration Policy at the AGM that year.

This "top-up" PSP award, equivalent to 25% of the CEO's base salary, was made to deliver in aggregate for 2020 an award level of 575% of base salary, increasing her award level from 550%. It was subject to the same business performance conditions as the main 2020 award, with a three-year performance period from 1 January 2020 to 31 December 2022. The main 2020 award vesting was announced on 14 February 2023. The "top-up" award has now vested on the same basis ie 52% vesting 48% lapsed, following the third anniversary of the grant. The vested shares are subject to a further two-year vesting period.

This notification that follows is for the "top-up" award made to the CEO and details the PSP conditional award that vested, including dividends accrued, on 9 May 2023. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £14.462.

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on the "top-up" award granted in 2020 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,729

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-05-09

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFUFLIEDSESI
Date   Source Headline
3rd May 20236:00 pmRNSUS FDA approves GSK’s RSV vaccine for older adults
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
2nd May 20233:00 pmRNSTotal Voting Rights
28th Apr 20235:01 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSGSK RSV OA vaccine gains positive EMA CHMP opinion
26th Apr 20237:00 amRNS1st Quarter Results
25th Apr 20237:00 amRNSEMA validates Jemperli filing for new indication
20th Apr 20233:30 pmRNSDirector/PDMR Shareholding
19th Apr 20233:30 pmRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSGSK reaches agreement to acquire BELLUS Health Inc
17th Apr 20233:30 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSGepotidacin positive phase III data
3rd Apr 20233:00 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSPositive phase III RUBY results for Jemperli
27th Mar 20231:00 pmRNSPublication of 2023 AGM Notice
24th Mar 20239:59 amRNSStatement: Zantac (ranitidine) litigation
21st Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20233:30 pmRNSDirector/PDMR Shareholding
14th Mar 20237:05 amRNSPositive phase III results for MenABCWY vaccine
14th Mar 20237:00 amRNSNucala NDA accepted for review in China
13th Mar 20233:30 pmRNSDirector/PDMR Shareholding
10th Mar 20234:26 pmRNSGSK Annual Report 2022 on Form 20-F
10th Mar 202310:36 amRNSGSK publishes Annual Report 2022
2nd Mar 20237:00 amRNSFDA Ad Com votes to support GSK RSV OA vaccine
1st Mar 20233:00 pmRNSTotal Voting Rights
27th Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSViiV Healthcare announces Cabenuva positive data
22nd Feb 20233:30 pmRNSDirector/PDMR Shareholding
16th Feb 20237:00 amRNSNEJM publishes GSK RSV OA vaccine candidate trial
15th Feb 20234:04 pmRNSDirector/PDMR Shareholding
15th Feb 20234:00 pmRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
10th Feb 20233:30 pmRNSDirector/PDMR Shareholding
10th Feb 20237:05 amRNSJemperli full FDA approval following GARNET trial
10th Feb 20237:00 amRNSJemperli FDA ODAC positive outcome
2nd Feb 20237:00 amRNSDaprodustat approved by US FDA for anaemia of CKD
1st Feb 20233:30 pmRNSDirector/PDMR Shareholding
1st Feb 20233:00 pmRNSTotal Voting Rights
1st Feb 20237:05 amRNSBenlysta granted Orphan Drug Designation by US FDA
1st Feb 20237:00 amRNSFinal Results
18th Jan 20233:30 pmRNSDirector/PDMR Shareholding
17th Jan 20233:30 pmRNSDirector/PDMR Shareholding
16th Jan 20233:30 pmRNSDirector/PDMR Shareholding
13th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12th Jan 20233:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.